Treatment Dosed Every 6 Months in Virologically Suppressed Adults With HIV-1 Infection
The study will evaluate the efficacy of switching to a regimen of single antiretroviral lenacapavir (LEN) in combination with two biologics Teropavimab and Zinlirvimab versus continuing on baseline oral ART.
Read more:
- https://www.nejm.org/doi/full/10.1056/NEJMoa2115542
- https://www.gilead.com/news-and-press/press-room/press-releases/2022/12/sunlenca-lenacapavir-receives-fda-approval-as-a-firstinclass-twiceyearly-treatment-option-for-people-living-with-multidrug-resistant-hiv
- https://clinicaltrials.gov/ct2/show/NCT04811040
- https://www.clinicaltrialsarena.com/news/gilead-sciences-hiv-therapy-trial/